上海岸邁生物與浙江特瑞思宣布合作開發(fā)岸邁生物雙特異性抗體項目FIT012
浙江特瑞思將獲得該產(chǎn)品中國開發(fā)權(quán)益，岸邁生物將擁有該產(chǎn)品除中國地區(qū)外的全球商業(yè)權(quán)益
2018.4.23 中國上海/蘇州，湖州----岸邁生物科技有限公司，一家總部位于上海的專注于雙特異性抗體開發(fā)的新興生物制藥公司，以及浙江特瑞思藥業(yè)股份有限公司，一家專門從事生物制劑研發(fā)的制藥公司，今天宣布將合作開發(fā)一項由岸邁生物開發(fā)的雙特異性抗體項目。根據(jù)雙方合作協(xié)議條款，浙江特瑞思藥業(yè)股份有限公司將獲得岸邁生物的FIT-Ig?雙抗項目FIT012 / TRS008的中國市場開發(fā)權(quán)益。岸邁生物將保留該項目除中國以外的全球商業(yè)權(quán)益。作為對中國商業(yè)化權(quán)益的回報，岸邁生物將獲得包括預(yù)付款在內(nèi)總額高達2100萬美元的里程碑付款，以及后續(xù)產(chǎn)品銷售提成。同時，岸邁生物將可能使用浙江特瑞思所提供的產(chǎn)品數(shù)據(jù)，用于在中國以外地區(qū)的產(chǎn)品開發(fā)或授權(quán)。
“除了岸邁生物目前正在進入臨床開發(fā)的領(lǐng)頭產(chǎn)品EMB01之外，F(xiàn)IT012將是岸邁目前經(jīng)過驗證的雙抗產(chǎn)品中進入臨床前和臨床開發(fā)的又一優(yōu)秀案例。”岸邁生物首席執(zhí)行官兼創(chuàng)始人吳辰冰博士表示，“特瑞思是該創(chuàng)新項目的理想合作伙伴，公司已經(jīng)證明了其在CMC方面的卓越能力，同時還擁有出色的早期臨床開發(fā)能力及多項成功IND申請的記錄。”
FIT012 / TRS008是一項針對腫瘤治療的雙特異性抗體項目。該項目是由岸邁生物開發(fā)并由特瑞思公司在一系列臨床前試驗中進行了驗證。FIT012 / TRS008的靶點目標(biāo)目前沒有披露。
“我們很高興與岸邁生物合作開發(fā)這個創(chuàng)新項目。 FIT012 / TRS008將非常適合我們公司的產(chǎn)品開發(fā)管線，” 浙江特瑞思藥業(yè)股份有限公司首席執(zhí)行官兼創(chuàng)始人吳幼玲表示，“除了我們公司自有的豐富的生物仿制藥和創(chuàng)新抗體產(chǎn)品管線外，像FIT012 / TRS008這一類高度創(chuàng)新的雙特異性抗體將讓我們能夠進一步擴大我們的產(chǎn)品管線?！?/p>
--歡迎和我們在第10屆生命科學(xué)合作會議ChinaBio?合作論壇上見面---岸邁生物將在星期三下午2點（2018年4月25）發(fā)表演講---欲了解更多信息，請訪問：
https://ebdgroup.knect365.com/chinabio-partnering/
關(guān)于岸邁生物科技有限公司
岸邁生物科技有限公司（EpimAb Biotherapeutics, Inc.）是一家私有的生物制藥研發(fā)公司，總部位于上海，其自主研發(fā)的FIT-Ig?(Fabs-In-Tandem Immunoglobulin)技術(shù)是一項獨特高效的開發(fā)雙特異性抗體產(chǎn)品的平臺技術(shù)?；谠摷夹g(shù)平臺，岸邁生物將開發(fā)一系列創(chuàng)新的雙抗藥物，主要針對腫瘤免疫和其他對于患者具備重要價值的治療領(lǐng)域。岸邁生物同時也將致力通過有選擇性的技術(shù)平臺授權(quán)，在全球范圍積極拓展多元化的合作。如需進一步信息，請訪問www.epimab.com
關(guān)于浙江特瑞思藥業(yè)股份有限公司
浙江特瑞思藥業(yè)股份有限公司（Zhejiang Teruisi Biopharmaceutical, Inc.）是一家以中國為基地的制藥公司，公司致力于開發(fā)生物大分子藥物，專注但不限于單克隆抗體產(chǎn)品開發(fā)以及其他生物藥商業(yè)生產(chǎn)，如生物仿制藥和創(chuàng)新生物藥等。憑借其強大的研發(fā)背景和專業(yè)知識，特瑞思期待著在生物制藥領(lǐng)域?qū)で笕蚝献骰锇椤?/p>
EpimAb Biotherapeutics and Zhejiang Teruisi Biopharmaceutical Announce Development Collaboration on Epimab’s FIT012 Bispecific Antibody Program
ZHEJIANG TERUISI BIOPHARMACEUTICAL TO TAKE THE LEAD IN DEVELOPING THE PROGRAM IN CHINA, EPIMAB RETAINS WORLDWIDE COMMERCIAL RIGHTS OUTSIDE OF CHINA
Shanghai/Suzhou, and Huzhou, China, April 23, 2018 - EpimAb Biotherapeutics, a Shanghai-based biopharmaceutical company specializing in bispecific antibodies, and Zhejiang Teruisi Biopharmaceutical, a company specialized in the development of biologics, today announced a development collaboration on a bispecific antibody program discovered by EpimAb. Under the terms of the agreement, Zhejiang Teruisi Biopharmaceutical, Inc. will gain access to EpimAb’s Fabs-In-Tandem Immunoglobulin (FIT-Ig?) program FIT012/TRS008 to develop it for the Chinese market. EpimAb retains all commercial rights to the program outside of China. In return for commercialization rights in China, EpimAb is eligible to receive an upfront payment and total success-based milestones of up to US-$21 MM, plus royalties. EpimAb may use the development data generated by Zhejiang Teruisi in partnering discussions outside of China for an undisclosed share of its net receipts. Further financial details were not disclosed.
“In addition to EMB01, EpimAb’s frontrunner program that is on its way to clinical development, FIT012 is another great example of EpimAb’s first validated assets moving forward into preclinical and clinical development,” said Dr. Chengbin Wu, CEO and founder of EpimAb. “Teruisi is an ideal partner for this innovative program and has proven its excellence in CMC capabilities with a successful track record of multiple IND filings as well as early clinical development.”
FIT012/TRS008 is a bispecific antibody program in oncology. The molecule was identified by EpimAb and validated by Zhejiang Teruisi Biopharmaceutical in an extensive series of preclinical tests. The targets of FIT012/TRS008 were not disclosed.
“We are delighted to work with EpimAb on this innovative program. FIT012/TRS008 will fit nicely in our development pipeline,” said Youling Wu, Chief Executive Officer and Founder of Zhejiang Teruisi Biopharmaceutical, Inc. “In addition to our rich pipeline of biosimilars and novel antibodies, a highly innovative bispecific antibody like FIT012/TRS008 will allow us to further expand our pipeline.”
--- Meet us at the 10th Annual International ChinaBio? Partnering Forum --- Epimab will present on Wednesday, 25 April 2018 at 2:00 pm CST --- For more info, please visit: https://ebdgroup.knect365.com/chinabio-partnering/
About EpimAb Biotherapeutics, Inc.
EpimAb Biotherapeutics is a privately-owned biopharmaceutical R&D company based in Shanghai with a proprietary unique and efficient technology called FIT-Ig? (Fabs-In-Tandem Immunoglobulin) to generate bispecific molecules with antibody-like properties. With this platform EpimAb is creating a pipeline of its own novel bispecific antibody therapeutics focused around immuno-oncology and other areas of high value to patients. EpimAb is also committed to diversifying its pipeline through selective licensing of its platform and pipeline assets to partners worldwide. For further information, please visit : www.epimab.com
About Zhejiang Teruisi Biopharmaceutical, Inc.
ZheJiang Teruisi Biopharmaceutical, Inc. is a Chinese based company that is developing biopharmaceuticals focusing on, but not limited, to monoclonal antibody product development and commercial manufacturing including biosimilars and innovate biopharmaceuticals. With its strong knowledge and expertise, Teruisi is looking forward to seeking partners worldwide in biopharmaceutical development.
Contact
EpimAb Biotherapeutics
Dr. Stephan Lensky, COO/CBO
Direct: +49 152 2610 7621
E-Mail: Stephan.lensky@epimab.com
ZheJiang Teruisi Biopharmaceutical
Dr. Youling Wu, CEO
Direct: +86 186 6810 9601
E-Mail: youling.wu@teruisipharm.com
For media:
MacDougall Biomedical Communications
Mario Brkulj or Amanda Houlihan
+49 89 2420 9345
or +1 781-235-3060?
epimab@macbiocom.com ?
